



Practitioner' Docket No. 2000DE443

RECEIVED  
JUL 28 2003  
TECH CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Peter KLUG, et al.

Application No.: 10/003,656

Group No.: 1617

Filed: November 29, 2001

Examiner: Wells, Lauren Q.

For: COSMETIC COMPOSITIONS COMPRISING ALK(EN)YLSUCCINIC ACID  
DERIVATIVES

#12  
AKO  
10/16/03

MAIL Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22202

Match and Return

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10\*  
(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22202.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10\*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_ (mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office (703) \_\_\_\_\_.

Date: 7-22-03

Signature

Vicki SGRO  
(type or print name of person certifying)

\*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).  
"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. ☒ Enclosures accompanying this Information Disclosure Statement are:
  - 1a. ☒ Form PTO-1449.
  - 1b. ☒ Copies of Information Disclosure Statement citations.
  - 1c. ☒ EPO Search Report
  - 1d. ☒ English language translation (complete or relevant portion(s) for each non-English language publication
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.

5. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☒ This Information Disclosure Statement is filed under 37 CFR § 1.97(d) after the Final Office Action or the Notice of Allowance, but before payment of the Issue Fee with the filing of a Request For Continued Examination(RCE). Accordingly, no fee or §1.97(e) Statement is required.
7. ☒ This is a continuation/divisional application under 37 CFR §1.53(d). The Issue Fee has not been paid.
8. ☒ In accordance with 37 CFR §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is enclosed as abstracts in the English language.

Respectfully submitted,



Richard P. Silverman  
Agent for the Applicant  
Registration No. 36,277

**Customer Number 25, 255**

Clariant Corporation  
Industrial Property Department  
4000 Monroe Road  
Charlotte, North Carolina 28205  
Telephone: 704/331-7156  
Facsimile: 704/331-7707

**RECEIVED**  
JUL 28 2003  
TECH CENTER 16

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (37 CFR 1.98(b))	ATTY. DOCKET NO. 2000DE443	SERIAL NO. 10/003,656
	APPLICANT: Peter KLUG, et al.	
	FILING DATE: 11/29/01	GROUP: 1617

## U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	3,412,111	11/19/68	Irwin, et al.	549	255	
	AB	4,369,123	1/18/83	Selwitz, et al.	516	53	
	AC	4,370,253	1/25/83	Selwitz, et al.	516	53	
	AD	4,698,065	10/6/87	Hoeffkes, et al.	8	406	
	AE	4,708,753	11/24/87	Forsberg, John	149	2	
	AF	5,580,553	12/3/96	Nakajima, Tohru	424	78.17	
	AG	2002/0039565		Aubrun-Sonneville et al.	424	70.11	See BB Below

## FOREIGN PATENT OR PUBLISHED FOREIGN APPLICATION

		DOCUMENT NUMBER	PUB. DATE	COUNTRY			TRANSLATION
	BA	EP 0 680 946	11/8/95	EPO			
	BB	EP 1 172 089	1/16/02	EPO			See AG Above
	BC	JP 63 020382	1/28/88	Japan			(Eng. Abstract)
	BD	JP 04 169565	6/17/92	Japan			(Eng. Abstract)
	BE	WO 02/055046	7/18/02	WIPO			(Eng. Abstract)

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication\*\*)

CA		Carey, J.M., et al., "Improved High Internal Phase Emulsions Using Alkenyl Succinic Anhydride Based Emulsifiers" Proceedings World Surfactants Congress, Vol. 2, pages 883-888, 29 May-2 June 2000
CB		
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		